Navigation Links
Clinical Trials, New Orders, Improved Services, and Approvals - Research Report on CareFusion, St. Jude Medical, Community Health Systems, Neurocrine Biosciences, and Alnylam Pharmaceuticals
Date:9/3/2013

any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

www.AnalystsCorner.com


'/>"/>
SOURCE Analysts' Corner
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Arena Pharmaceuticals Completes Phase 1b Clinical Trial Evaluating APD811 for Pulmonary Arterial Hypertension
2. Magellan Diagnostics Receives FDA Clearance for LeadCare Ultra Bench-top Clinical Lead Analyzer
3. Cellular Biomedicine Group Announces Completion of Patient Enrollment for Phase I Clinical Trial for Liver Cancer
4. Selexys Pharmaceuticals Initiates SUSTAIN Phase 2 Clinical Trial in Sickle Cell Patients with Pain Crises
5. Final Patient Completes Prosonix Phase 2 Clinical Study with PSX1002 in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
6. Ampio Pharmaceuticals, Inc. Announces Positive Results for Ampion in Osteoarthritis of the Knee Clinical Trial
7. Start-up Seeks Crowd Funding to Complete Clinical Studies Supporting Breakthrough Blood Test for Earlier Detection of Melanoma
8. MacroGenics Appoints Jon Wigginton, M.D., as Senior Vice President, Clinical Development
9. Neuralstem Reports Second Quarter Financial Results And Provides Business And Clinical Update
10. Sanarias Malaria Vaccine Yields Unprecedented Protection In Phase 1 Clinical Trial
11. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for Second Quarter 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... Lifesciences Corporation (NYSE: EW ), the global leader ... today reported net income for the quarter ended June 30, ... Adjusted net income on a non-GAAP basis was $124.4 ... per diluted share in the prior year period. In ... per diluted share, which included a $750 million payment ...
(Date:7/28/2015)... LA JOLLA, Calif. , July 28, 2015 /PRNewswire/ ... a biopharmaceutical company leading the discovery and development of ... report financial results and highlights for the quarter ended ... the U.S. financial markets close. Regulus ... August 4, 2015, at 5:00 pm Eastern Daylight Time ...
(Date:7/28/2015)... -- Express Scripts Holding Company (Nasdaq: ESRX ) announced ... stockholders of $600.1 million, or $0.88 per diluted share.  ... 4, were $1.44 for the second quarter. 1  ... healthcare are validating the need for size and scale," ... what matters most is how that size and scale ...
Breaking Medicine Technology:Edwards Lifesciences Reports Second Quarter Results 2Edwards Lifesciences Reports Second Quarter Results 3Edwards Lifesciences Reports Second Quarter Results 4Edwards Lifesciences Reports Second Quarter Results 5Edwards Lifesciences Reports Second Quarter Results 6Edwards Lifesciences Reports Second Quarter Results 7Edwards Lifesciences Reports Second Quarter Results 8Edwards Lifesciences Reports Second Quarter Results 9Edwards Lifesciences Reports Second Quarter Results 10Edwards Lifesciences Reports Second Quarter Results 11Edwards Lifesciences Reports Second Quarter Results 12Edwards Lifesciences Reports Second Quarter Results 13Edwards Lifesciences Reports Second Quarter Results 14Edwards Lifesciences Reports Second Quarter Results 15Edwards Lifesciences Reports Second Quarter Results 16Edwards Lifesciences Reports Second Quarter Results 17Edwards Lifesciences Reports Second Quarter Results 18Edwards Lifesciences Reports Second Quarter Results 19Edwards Lifesciences Reports Second Quarter Results 20Edwards Lifesciences Reports Second Quarter Results 21Edwards Lifesciences Reports Second Quarter Results 22Edwards Lifesciences Reports Second Quarter Results 23Regulus Announces Timing for Second Quarter 2015 Financial Results Webcast and Conference Call 2Regulus Announces Timing for Second Quarter 2015 Financial Results Webcast and Conference Call 3Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 2Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 3Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 4Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 5Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 6Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 7Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 8Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 9Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 10Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 11Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 12
... , , NATICK, Mass. and ... BSX ) today announced that it has received ... (FDA) and CE Mark approval to market its WallFlex® ... esophageal strictures (obstructions) caused by tumors in patients with ...
... Nov. 20 BD (Becton, Dickinson and Company) (NYSE: ... its acquisition of HandyLab, Inc., an Ann Arbor, Michigan-based ... automation platforms. , In May 2009, BD and HandyLab ... commercialize molecular assays on the HandyLab Jaguar(TM) platform, the ...
Cached Medicine Technology:Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 2Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 3Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 4BD Completes Acquisition of HandyLab, Inc. 2BD Completes Acquisition of HandyLab, Inc. 3
(Date:7/29/2015)... ... July 29, 2015 , ... San Fernando Valley skin doctor , Dr. ... time only, patients can get the complete treatment process with a 10 percent discount ... non-invasive treatment and have loose or sagging skin. , As the only non-surgical ...
(Date:7/29/2015)... ... July 29, 2015 , ... Today marks a significant achievement in bringing ... growth companies and is led by a group of experienced investors, has tapped into ... with their dollars to be a part of the fund. The Sofia Fund ...
(Date:7/29/2015)... ... July 29, 2015 , ... CanAm Enterprises, LLC (“CanAm”) is thrilled ... past month! I-829 approvals have been granted to investors in four different CanAm EB-5 ... Lafayette Hotel project in Philadelphia, and the Valley Forge Convention Center project in CanAm’s ...
(Date:7/29/2015)... Los Angeles, CA (PRWEB) , ... July 29, ... ... mission to Honduras with the Hackett Hemwall Foundation in March, Steven W. Meier ... offer pro bono prolotherapy treatments to qualifying patients with demonstrated financial need. , ...
(Date:7/29/2015)... ... July 29, 2015 , ... Employee Fiduciary, LLC announces ... the general contact information, website, types of plans administered, years in business, and credentials ... and have at least one plan with Employee Fiduciary. A search can be done ...
Breaking Medicine News(10 mins):Health News:San Fernando Valley Dermatology Office, Castle Dermatology Institute, is Now Offering a Promotional Price on Ultherapy 2Health News:Sofia Fund Surpasses Investor Goals 2Health News:More Than 60 New I-829 Approvals in Less Than 30 days for CanAm 2Health News:More Than 60 New I-829 Approvals in Less Than 30 days for CanAm 3Health News:Orthopedic Surgeon Announces New Pro Bono Prolotherapy and Regenerative Medicine Clinic for Underserved Communities in Los Angeles 2Health News:Employee Fiduciary Launches Financial Advisor Directory 2
... , TACOMA, Wash. , Feb. 4 ... quality review possible by the Food and Drug Administration (FDA) for ... by the Mammography Quality Standards Act (MQSA).  Receiving the "All Items ... percent of U.S. breast programs have not received this high quality ...
... , FORT WORTH, Texas , Feb. ... during the holidays, RadioShack has collected more than $1.3 ... fights for the 28 million people around the world living ... which promotes cancer prevention, detection and treatment across the globe. ...
... Radiation Oncology (ASTRO) and the American College of ... guided radiation therapy (IGRT) and stereotactic body radiation ... International Journal of Radiation Oncology*Biology*Physics, the ... as educational tools to assist practitioners in providing ...
... is the second leading cause of cancer-related deaths in the ... screening for this disease, rates of screening for colorectal cancer ... particularly breast and cervical. Although the screening rates in the ... 20-30 percent in 1997 to nearly 55 percent in 2008 ...
... new way to repair damage with natural tissue , ... gel that promotes cartilage growth in joints has been ... into the damaged joint and stimulates bone marrow stem ... expensive growth factors. No current therapy can do this, ...
... need to be cut to 16 to avoid medical errors ... Helen Haskell took her 15-year-old son to a teaching university ... he was dead. The cause: failure to rescue, meaning, Haskell ... act upon declines in patients." , He was cared for ...
Cached Medicine News:Health News:Carol Milgard Breast Center Awarded Highest Government Rating for Mammography Sites 2Health News:RadioShack Customers Donate $1.3 Million to LIVESTRONG 2Health News:ASTRO, ACR issue IGRT, SBRT guidelines 2Health News:Panel calls for reducing colorectal cancer deaths by striking down barriers to screening 2Health News:Nanofiber Gel May Spur Growth of New Knee Cartilage 2Health News:Campaign Calls for Limits on Doctors' Hours 2Health News:Campaign Calls for Limits on Doctors' Hours 3
Biosite continues its tradition of leadership and innovation with the development of the Triage TOX Drug Screen. This breakthrough technology sets new standards for clear, convenient and controlled,...
... Advanced Model 3900 Multi-Sample Osmometer is ... processing moderate to high volumes of ... of freezing-point technology for an accurate ... high, continuous throughput, the Advanced Instruments ...
... Advanced® Model 3320 Micro-Osmometer is an automated, ... sample. The Model 3320 is ideally suited ... quantity is limited.The Model 3320 employs the ... proven to be robust and dependable throughout ...
... Advanced® 2020 Multi-Sample Osmometer provides extremely ... and research settings. These results are ... method, which determines total concentration. Only ... data management, automated sample handling, and ...
Medicine Products: